Tumor Infiltrating Lymphocytes

Phase 2Cell therapy

EEssen Biotech

Tumor Infiltrating Lymphocytes is one of 409 small molecule programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

408

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaRecruiting

Lung CancerRecruiting

Esophageal CancerRecruiting

Brain CancerRecruiting

Uveal MelanomaRecruiting

Biliary Tract CancerRecruiting

Rectum CancerRecruiting

Non-Small Cell Lung CancerRecruiting

Breast CancerCompleted

Solid TumorRecruiting

GliomaPhase 1

Recruiting

Lung CancerPhase 2

Recruiting

Esophageal CancerPhase 2

Recruiting

Brain CancerPhase 2

Recruiting

Uveal MelanomaPhase 2

Recruiting

Biliary Tract CancerPhase 2

Recruiting

Rectum CancerPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 1

Recruiting

Breast CancerPhase 2

Completed

Solid TumorPhase 1

Recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tumor Infiltrating Lymphocytes

EEssen Biotech

Phase 2

3 2

Voltaren

Novartis

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Acupan

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Esophageal Cancer

NCT06532799

Phase 1/2Recruiting

Breast Cancer

NCT06532812

Phase 1/2Recruiting

Lung Cancer

NCT06538012

Phase 1/2Recruiting

Rectum Cancer

NCT06530303

Phase 1/2Recruiting

Brain Cancer

NCT06640582

Q2 2027

Phase 1Recruiting

Glioma

NCT04943913

Clinical

Trials by Indication[1]

Metastatic Melanoma5 trials

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01369888·3 enrolled

Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy

Unknown status·HHadassah Medical Organization·Phase 2·NCT00604136·20 enrolled

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01369875·2 enrolled

Show 2 more trials

A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas

Terminated·SSaint John's Cancer Institute·Phase 2·NCT02375984·1 enrolled

Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma

Terminated·WWake Forest University Health Sciences·Phase 2·NCT00863330·14 enrolled

Breast Cancer3 trials

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

Completed·YYale University·Phase 2·NCT04111510·6 enrolled

A Study of GC101 TIL in Advanced Breast Cancer (10hospital)

Recruiting·SShanghai Juncell Therapeutics·Phase 1·NCT05142475·50 enrolled

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Recruiting·EEssen Biotech·Phase 1/2·NCT06532812·85 enrolled

Ovarian Cancer2 trials

Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer

Unknown status·LLeiden University Medical Center·Phase 1/2·NCT04072263·12 enrolled

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Terminated·IInge Marie Svane·Phase 1/2·NCT04611126·6 enrolled

Solid Tumor2 trials

A Clinical Study to Evaluate the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes Injection in Patients With Advanced Malignant Solid Tumors

Recruiting·SShanghai Juncell Therapeutics·Phase 1·NCT04967833·20 enrolled

A Clinical Study on Tumor Infiltrating Lymphocytes for the Treatment of Advanced Solid Tumors

Recruiting·SShanghai Juncell Therapeutics·Phase 1·NCT05087745·50 enrolled

Advanced Solid Tumors1 trial

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Not yet recruiting·FFujian Cancer Hospital·Phase 1·NCT05649618·42 enrolled

16 more indications

Patients With Advanced Solid Tumors1 trial

TIL Therapy for Patients With Advanced Solid Tumors

Not yet recruiting·NNeogenTC·Phase 1·NCT06107894·12 enrolled

Pilot Study1 trial

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Terminated·YYale University·Phase 1·NCT03526185·6 enrolled

Melanoma1 trial

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Completed·UUniversity Health Network, Toronto·Phase 2·NCT01883323·12 enrolled

Intestinal Cancer1 trial

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Completed·IIntima Bioscience, Inc.·Phase 1/2·NCT04426669·23 enrolled

Esophageal Cancer1 trial

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Recruiting·EEssen Biotech·Phase 1/2·NCT06532799·75 enrolled

Lung Cancer1 trial

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

Recruiting·EEssen Biotech·Phase 1/2·NCT06538012·85 enrolled

Rectum Cancer1 trial

Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer

Recruiting·EEssen Biotech·Phase 1/2·NCT06530303·85 enrolled

Brain Cancer1 trial

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Recruiting·EEssen Biotech·Phase 1/2·NCT06640582·85 enrolled

Glioblastoma Multiforme1 trial

The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1·NCT05333588·20 enrolled